早期乳腺癌保乳手术中靶向术中放疗:一项II期单中心前瞻性试验
该II期单中心前瞻性试验纳入61例≥50岁、激素受体阳性、1或2级、cT1N0浸润性导管癌患者,保乳术后立即行20 Gy单次靶向术中放疗;最终病理低危者不再外照射,高危者追加15至16次全乳外照射。中位随访3.9年,两组均无4级放疗毒性,局部区域复发率均为0%,总生存率低危组97.5%、高危组95.2%,无显著差异。
要点
- 保乳术后立即行20 Gy单次靶向术中放疗,低危者不再外照射,高危者追加全乳外照射。
- 两组均无4级放疗毒性,最常见术后并发症均为血清肿和蜂窝织炎。
- 中位随访3.9年,两组局部区域复发率均为0%,总生存率无显著差异。
核心结论
- 在行保乳手术的早期乳腺癌患者中,使用靶向术中放疗显示较低的放疗毒性和术后并发症发生率。
- 中位随访3.9年的短期结果显示,单纯靶向术中放疗组与靶向术中放疗后追加全乳外照射组在局部区域复发或总生存方面无显著差异。
- 全部患者中34.4%需要追加全乳外照射,最常见原因为切缘近。
研究设计与样本
- 麦吉尔大学健康中心开展的前瞻性II期单中心试验。
- 纳入年龄≥50岁、活检证实激素受体阳性、1或2级、浸润性导管癌、cT1N0的早期乳腺癌患者。
- 入组患者行保乳手术后立即接受20 Gy单次靶向术中放疗。
- 最终病理为低危乳腺癌者不再接受外照射,高危乳腺癌者追加15至16次全乳外照射。
- 高危标准包括病理肿瘤大小>2 cm、3级、淋巴血管侵犯阳性、多灶性疾病、切缘近(<2 mm)或淋巴结阳性。
主要发现
- 共入组61例早期乳腺癌患者,最终病理低危40例(65.6%),高危21例(34.4%)。
- 中位随访3.9年。
- 最常见的高危标准为切缘近66.6%(n=14)和淋巴血管侵犯28.6%(n=6)。
- 两组均未观察到4级放疗毒性,最常见的术后并发症均为血清肿和蜂窝织炎。
- 两组局部区域复发率均为0%;总生存率低危组97.5% vs 高危组95.2%,无显著差异;死亡均非乳腺癌相关。
关键数值与推荐
- 靶向术中放疗剂量为20 Gy单次。
- 高危乳腺癌追加全乳外照射15至16次。
- 高危标准包括病理肿瘤大小>2 cm、3级、淋巴血管侵犯阳性、多灶性疾病、切缘近(<2 mm)或淋巴结阳性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with early stage breast cancer (ESBC) are conventionally treated with breast-conserving surgery (BCS) followed by whole-breast external beam radiation therapy (EBRT). The emergence of targeted intraoperative radiation therapy (TARGIT) with Intrabeam has been used as a therapeutic alternative for patients with risk-adapted ESBC. Here we present our radiation therapy toxicities (RTT), postoperative complications (PC), and short-term outcomes of the prospective phase II trial at the McGill University Health Center. METHODS AND MATERIALS: Patients aged ≥50 years with biopsy-proven hormone receptor-positive, grade 1 or 2, invasive ductal carcinoma of the breast, cT1N0, were eligible for the study. Enrolled patients underwent BCS followed by immediate TARGIT of 20 Gy in 1 fraction. Upon final pathology, patients with low-risk breast cancer (LRBC) received no further EBRT, and those with high-risk breast cancer (HRBC) received further 15 to 16 fractions of whole breast EBRT. HRBC criteria included pathologic tumor size >2 cm, grade 3, positive lympho-vascular invasion, multifocal disease, close margins (<2 mm), or positive nodal disease. RESULTS: A total of 61 patients with ESBC were enrolled in the study; upon final pathology, 40 (65.6%) had LRBC, and 21 (34.4%) had HRBC. The median follow-up was 3.9 years. The most common HRBC criteria were close margins in 66.6% (n = 14) and lymphovascular invasion in 28.6% (n = 6). No grade 4 RTT were observed in either group. The most common PC were seroma and cellulitis for both groups. The rate of locoregional recurrence was 0% in both groups. The overall survival in LRBC was 97.5% and in HRBC 95.2% with no significant differences. Deaths were nonbreast cancer related. CONCLUSIONS: In patients with ESBC undergoing BCS, the use of TARGIT shows low rates of RTT and PC complications. Moreover, our short-term outcomes show no significant difference at 3.9 years median follow-up for locoregional recurrence or overall survival between groups of patients receiving TARGIT alone or TARGIT followed by EBRT. Of all patients, 34.4% required further EBRT, most commonly due to close margins.
引用
- Martinez C, Meterissian S, Saidi A, et al. Targeted Intraoperative Radiation Therapy during Breast-Conserving Surgery for Patients with Early Stage Breast Cancer: A Phase II Single Center Prospective Trial. Adv Radiat Oncol. 2023. PMID: 37408681. doi:10.1016/j.adro.2023.101236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。